Dry and Wet Age-Related Macular Degeneration – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of AMD comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of AMD for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.
All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology’s AMD forecast answers the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of AMD and the number of new diagnoses of AMD?
- Of all people diagnosed with AMD, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AMD over the forecast period?
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following AMD subpopulations:
- Total prevalent cases of AMD.
- Total prevalent cases of early AMD.
- Total prevalent cases of intermediate AMD.
- Total prevalent cases of late AMD.
- Total prevalent cases of wet AMD.
- Total prevalent cases of geographic atrophy.
- Total prevalent cases of dry AMD.
- Diagnosed prevalent cases of geographic atrophy.
- Diagnosed prevalent cases of wet AMD.
- Drug-treated prevalent cases by geographic atrophy.
- Drug-treated prevalent cases of wet AMD.
- Non-drug-treated prevalent cases by geographic atrophy.
- Non-drug-treated prevalent cases of wet AMD.
Note: Coverage may vary by country.
